Neurotech International Ltd (nti) Logo

Neurotech International Ltd (NTI)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

NTI Chart

NTI's Principal Activity is the neurotech researches, designs, markets and through third party manufacturers, produces wearable neurotechnology devices to assist with neurological conditions such as autism.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +458.82%
vs ASX 200 (1yr) +445.34%

Size

Market Capitalisation
ASX Rank 1,460 of 2,295
Sector Rank 130 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies VIP / ADR / IMC
EPS -$0.012
DPS $0.00
NTA per share $0.00

Broker Consensus

NTI is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Neurotech International Limited (NTI) is a medical device and solutions company whose primary mission is to improve the lives of people with neurological conditions. NTI operates in one segment being Medical Device Development and Distribution. The Company incorporated in Australia, operating through its wholly-Owned, malta-based subsidiary, AAT Research Limited.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Nedlands WA 6009
Website www.neurotechinternational.com
Registry Automic Group
Auditor BDO Audit (WA) Pty Ltd
Date Listed 4 Nov 2016

Upcoming Calendar (Forecasted)

Date Event
30/08/2021 Report (Prelim)
30/08/2021 Report (Annual)
25/02/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Professor Allan Cripps Non-Executive Director May 2021 Director Bio icon

Professor Allan Cripps

Non-Executive Director

Prof Cripps is currently a Professor Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University, Australia. He is a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland at Griffith University, Australia. He has gained experience working as a clinical scientist, academic and health services executive and has made contributions in immunology, vaccine development, diagnostics health services delivery and professional health education. Prof Cripps has experience in the development of immunity in children and mucosal immune mechanisms, in recent years he has contributed to the field of immunology through translational research and human clinical studies. Prof Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer-reviewed scientific papers and presented them at many national and international scientific conferences. In 2012 he launched the first international peer-reviewed journal focused on pneumonia as a means for bringing together knowledge related to pathogenesis, treatment and prevention of this disease and remains the Journals Founding Editor. Prof Cripps is a member of the journal VACCINE Council of 100. This Council is made up of 100 of the world's vaccine researchers and clinicians and provides advice on vaccine development to both the Journal and other organisations globally. He is also a member of the Immunisation Coalition and a member of the Coalition's Scientific Advisory Committee and is currently appointed to industry advisory boards for advice on strategies related to the development of vaccines for respiratory infections in children and adults including those with chronic lung conditions.

Ms Krista Bates Non-Executive Director Apr 2021 Director Bio icon

Ms Krista Bates

Non-Executive Director

Ms Bates is an experienced non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and various private companies in multiple jurisdictions. She has a legal background with over 20 years' experience in the legal market, with experience working in emerging markets in both a commercial and legal capacity. Ms Bates is currently a Non-executive Director of AusCann Holdings (ASX:AC8) and Australia-Africa Minerals & Energy Group. She is also a Corporate Partner at Lavan law firm, where she is Head of Mining & Resources Group and Head of Medical Cannabis Group. Formerly, she has held both Executive and Non-executive Directorship roles at Credit Intelligence (ASX:CI1) and Fastjet, London, Nairobi, Harare and Dar es Salaam (LSE:FJET), and has held Corporate Partner roles at Anjarwalla & Khanna (Nairobi, Kenya) and Clyde & Co (London and Dar es Salaam, Tanzania).

Mr Brian Willoughby Leedman Non-Executive Chairman,Non-Executive Director Oct 2020 Director Bio icon

Mr Brian Willoughby Leedman

Non-Executive Chairman,Non-Executive Director

Mr Leedman has over 15 years' experience in the biotechnology sector. Mr Leedman is formerly the Chairman (WA) of Ausbiotech, Founder and Executive Director of ResApp Health, Founder of Oncosil Medical and Biolife Sciences Limited (acquired by Imugene Limited) and Nonexecutive Director of Alcidion Corporation. He is presently the Chairman or NeuroScientific Biopharmaceuticals and Chairman of Nutritional Growth Solutions.

Mr Winton William Willesee Non-Executive Director Apr 2019 Director Bio icon

Mr Winton William Willesee

Non-Executive Director

Mr Willesee is an experienced corporate professional with a range of skills and experience strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance. Mr Willesee has experience with ASX listed and other companies over a range of industries, having held directorships, chairmanships and company secretarial positions with a number of ASX-listed companies over many years.

Mr Mark Davies Non-Executive Director Apr 2019 Director Bio icon

Mr Mark Davies

Non-Executive Director

Mr Davies has over 20 years experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.

Ms Erlyn Dale Company Secretary Apr 2019

Director Transactions

NTI directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
14/07/21 Allan Cripps Buy +180,000 $0.056 $10,017 On-market trade
14/07/21 Krista Bates Buy +180,000 $0.056 $10,044 On-market trade
22/06/21 Brian Leedman Buy +933,589 $0.054 $49,961 On-market trade
13/04/21 Krista Bates Buy +270,000 $0.074 $19,980 On-market trade
22/12/20 Brian Leedman Issued 2,272,727 $0.022 $49,999 Placement
17/12/20 Winton Willesee Issued 2,000,000 $0.056 $112,000 Issue of options
17/12/20 Mark Davies Issued 2,000,000 $0.056 $112,000 Issue of options
17/12/20 Brian Leedman Issued 20,000,000 $0.056 $1,120,000 Issue of options
05/10/20 Winton Willesee Transfer 1,252,852 $0.013 $16,287 Off-market transfer
05/10/20 Winton Willesee Issued 6,047,382 $0.008 $48,500 Director remuneration
30/09/20 Peter Griffiths Issued 16,957,606 $0.008 $136,000 Director remuneration
30/09/20 David Cantor Issued 4,551,122 $0.008 $36,499 Director remuneration
30/09/20 Mark Davies Issued 7,793,017 $0.008 $62,499 Director remuneration
18/11/19 David Cantor Buy +2,000,000 $0.014 $28,000 As advised by the company
18/11/19 Mark Davies Buy +2,000,000 $0.014 $28,000 As advised by the company
18/11/19 Winton Willesee Buy +2,000,000 $0.014 $28,000 As advised by the company
18/11/19 Peter Griffiths Buy +11,929,754 $0.014 $167,017 As advised by the company
25/02/19 Peter O'Connor Issued 503,100 $0.026 $13,081 Rights issue
25/02/19 Peter Griffiths Issued 2,634,790 $0.03 $79,044 Rights issue
25/02/19 Simon Trevisan Issued 3,333,334 $0.03 $100,000 Rights issue
25/02/19 Peter Griffiths Issued 2,634,790 $0.026 $68,505 Rights issue
25/02/19 Peter O'Connor Issued 503,100 $0.03 $15,093 Rights issue
25/02/19 Simon Trevisan Issued 3,333,334 $0.026 $86,667 Rights issue
04/12/18 David Cantor Issued 142,857 $0.14 $20,000 Issue of securities

Director Interests

The current holdings of NTI directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Krista Bates 14/07/2021 450,000 N/A N/A N/A
Allan Cripps 14/07/2021 180,000 N/A N/A N/A
Brian Leedman 22/06/2021 2,272,727 933,589 20,000,000 N/A
Mark Davies 17/12/2020 0 7,793,017 4,000,000 N/A
Winton Willesee 17/12/2020 N/A 5,132,436 4,000,000 N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Aug 1, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
J & J Bandy Nominees Pty Ltd <Bandy P/F A/C> 22,670,720 9.16%
Jalaver Pty Ltd <Falcon Pension A/C> 20,700,000 8.36%
Chincherinchee Nominees Pty Ltd 12,596,786 5.09%
Tribis Pty Ltd 8,738,434 3.53%
Citicorp Nominees Pty Limited 6,774,512 2.74%
Br Corporation Pty Ltd 5,925,000 2.39%
Clayton Capital Pty Ltd 5,000,000 2.02%
Siawade Pty Ltd 4,000,000 1.62%
Mr Bo He 3,652,290 1.48%
Surf Coast Capital Pty Ltd <Minnie Pension Fund A/C> 3,250,000 1.31%
Miss Elisabeth Jane D'Sylva 3,200,000 1.29%
J & J Bandy Nominees Pty Ltd <J & J Bandy Super Fund A/C> 3,000,000 1.21%
Mr Alexander Grech 2,965,624 1.20%
Empire Capital Partners Pty Ltd 2,859,012 1.16%
Comsec Nominees Pty Limited 2,456,178 0.99%
Windell Holdings Pty Ltd <Thompson Super Fund A/C> 2,315,000 0.94%
Tyf Holdings Pty Ltd <Tyf Investment A/C> 2,000,000 0.81%
Mr Rohan Charles Edmondson 2,000,000 0.81%
Mrs Sugandi Witharanage Rodrigo 2,000,000 0.81%
Robert Michael Baker <Robert Baker Family A/C> 2,000,000 0.81%
Sabreline Pty Ltd <Jpr Investment A/C> 2,000,000 0.81%
Demasiado Pty Ltd <Demasiado Family A/C> 2,000,000 0.81%
Heritage Pacific Pty Ltd 2,000,000 0.81%
Hitmaster Pty Ltd 2,000,000 0.81%
Mr Bilal Ahmad 2,000,000 0.81%
Max Cap Investments Pty Ltd 2,000,000 0.81%
Flourish Super Pty Ltd <Flourish S/F A/C> 1,957,778 0.79%
Gianfam Investments Pty Ltd <Mark Giannarelli Family A/C> 1,900,000 0.77%
Mr Duncan Thain Craib <Erracht A/C> 1,753,008 0.71%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 25 135 110 464 257 991

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Shimano Ventures Limited 30/09/2020 24,249,984 6.24

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
30-09-20 Shimano Ventures Limited 24,249,984 -- 6.24

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
12-11-20 J and J Bandy Nominees Pty Ltd 23,344,887 10.85 --
12-11-20 Jalaver Pty Ltd 22,645,178 10.52 --
07-09-20 Bonvoyolo Pty Ltd 12,596,786 5.85 --
30-07-20 Stephen J Dobson 15,096,786 7.01 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.008 30 June
2019 $0.018 28 June
2018 $0.16 29 June
2017 $0.25 28 June
Page Icon
NTI Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.